The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksB&M Regulatory News (BME)

Share Price Information for B&M (BME)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 521.60
Bid: 521.80
Ask: 522.20
Change: 4.60 (0.89%)
Spread: 0.40 (0.077%)
Open: 519.80
High: 525.00
Low: 517.20
Prev. Close: 517.00
BME Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of Senior Secured Notes Offering

23 Jan 2017 07:56

RNS Number : 8162U
B&M European Value Retail S.A.
23 January 2017
 

 

 

 

23 January 2017

 

B&M European Value Retail S.A.

 

B&M Launches £250 Million Senior Secured Notes Offering

 

 

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF B&M EUROPEAN RETAIL VALUE S.A. THIS ANNOUNCEMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. 

 

B&M European Value Retail S.A. (the "Company") (BME:LN) announces today that it intends to offer sterling-denominated senior secured notes in an aggregate principal amount of approximately £250 million due 2022 (the "Notes").

 

The Notes will be offered in connection with the refinancing of certain of the Company's existing senior credit facilities. The existing facilities will be replaced by new senior credit facilities, which will include a £300 million term loan facility and £150 million revolving credit facility. If successful, the proceeds from the offering of the Notes, together with the new term loan A facility and cash on hand, will be used to refinance all of the the existing senior facilities, to pay fees and expenses relating to the refinancing, including the offering of the Notes, and for general corporate purposes.

 

This announcement includes inside information which is disclosed in accordance with the Market Abuse Regulation.

 

 

Enquiries

 

 

B&M European Value Retail S.A.

For further information please contact +44 (0) 151 728 5400 Ext 5766

Simon Arora, Chief Executive

Paul McDonald, Chief Financial Officer

Steve Webb, Investor relations Director

investor.relations@bandmretail.com

 

Media

For media please contact +44 (0) 207 379 5151

Maitland

Robbie Hynes

bmstores-maitland@maitland.co.uk

 

 

Important Notice

 

No communication and no information in respect of the offering by B&M European Value Retail S.A. of notes described in this announcement (the "Notes") may be distributed to the public in any jurisdiction where a registration or approval is required. No steps have been or will be taken in any jurisdiction where such steps would be required. The offering or sale of the Notes may be subject to specific legal or regulatory restrictions in certain jurisdictions. B&M European Value Retail S.A. takes no responsibility for any violation of any such restrictions by any person.

This announcement is not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament ant the Council of November 4, 2003 as implemented in each member State of the European Economic Area and amendments thereto, including Directive 2010/73/EU (the "Prospectus Directive").

This announcement does not, and shall not, in any circumstances constitute a public offering nor an invitation to the public in connection with any offer in any jurisdiction.

With respect to the member States of the European Economic Area which have implemented the Prospectus Directive, the Notes may only be offered under circumstances not requiring B&M Retail Value S.A. to publish a prospectus as provided under article 3(2) of the Prospectus Directive.

This communication does not constitute an offer to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the Notes. The distribution of this press release is not made, and has not been approved, by an "authorized person" within the meaning of Section 21(1) of the Financial Services and Markets Act 2000. As a consequence, this press release is directed only at persons who (i) are located outside the United Kingdom, (ii) have professional experience in matters relating to investments and fall within Section 19(5) ("investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (the "Order") , (iii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order or (iv) are persons to whom this communication may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). The Notes are directed only at Relevant Persons and no invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes may be proposed or made other than with Relevant Persons. Any person other than a Relevant Person may not act or rely on this document or any provision hereof. This press release is not a prospectus which has been approved by the Financial Conduct Authority or any other United Kingdom regulatory authority for the purposes of Section 85 of the Financial Services and Markets Act 2000.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful. There will be no public offering of the notes. The notes are being offered only to qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933 (the "Securities Act") and outside the United States pursuant to Regulation S under the Securities Act. The Notes have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons, as such term is defined in Regulation S under the Securities Act ("Regulation S"), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act.

The distribution of this document in certain countries may constitute a breach of applicable law. The information contained in this document does not constitute an offer of securities for sale in the United States, Australia, Canada or Japan.

This press release may not be published, forwarded or distributed in the United States, Australia, Canada or Japan.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IODUOVBRBVAAURR
Date   Source Headline
18th Jul 202311:00 amRNSBlock Listing Application
13th Jul 20231:46 pmRNSBlock listing Interim Review
30th Jun 20239:00 amRNSTotal Voting Rights
29th Jun 20237:00 amRNSQ1 FY24 Trading update
20th Jun 202310:01 amRNSBoard Appointment
20th Jun 20238:30 amRNSNotice of FY24 First Quarter Trading Statement
19th Jun 20237:00 amRNSAnnual Financial Report and Notices of AGM and EGM
13th Jun 20234:03 pmRNSDirector/PDMR Shareholding
31st May 20237:05 amRNSRetirement of Director after AGM
31st May 20237:00 amRNSFY23 Preliminary Results
22nd May 20236:08 pmRNSTR1- Notification of major holdings
21st Apr 202310:35 amRNSBoard Change
17th Apr 20234:28 pmRNSTiming of Preliminary Results Announcement
3rd Apr 20233:00 pmRNSNotice to Noteholders
3rd Apr 20232:59 pmRNSBank Facility Extension
16th Feb 20235:37 pmRNSPDMR Share Purchase
13th Jan 20231:09 pmRNSBlock listing Interim Review
11th Jan 20233:46 pmRNSDirector Dealing: Purchase of Bonds
10th Jan 20233:23 pmRNSDirector/PDMR Shareholding
5th Jan 20237:00 amRNSStrong Q3 FY23 Trading
14th Dec 20221:59 pmRNSDirector Dealing: Purchase of Bonds
9th Dec 202211:43 amRNSNotice of FY23 Third Quarter Trading Statement
18th Nov 20229:14 amRNSDirector/PDMR Shareholding
10th Nov 20227:00 amRNSHalf-year Report
2nd Nov 202212:06 pmRNSConfirmation of timing of Interim Results
31st Oct 20229:23 amRNSAppointment of directors- Result of Meeting
18th Oct 20223:51 pmRNSHolding(s) in Company
30th Sep 20227:00 amRNSTotal Voting Rights
27th Sep 20227:00 amRNSNotice of GM
15th Sep 20228:20 amRNSManagement Succession and Board Update
9th Sep 20222:17 pmRNSDirector/PDMR Shareholding
31st Aug 20223:06 pmRNSDirector/PDMR Shareholding
31st Aug 20223:01 pmRNSTotal Voting Rights
18th Aug 20227:00 amRNSBoard Appointment and Retirement
5th Aug 20224:41 pmRNSDirector/PDMR Shareholding
4th Aug 20227:00 amRNSAppointment of Joint Corporate Broker
3rd Aug 202212:12 pmRNSTR1 Notification
29th Jul 202210:28 amRNSAGM Voting Results
14th Jul 202212:07 pmRNSBlock Listing Application
13th Jul 20223:48 pmRNSBlock listing Interim Review
5th Jul 20227:00 amRNSBoard appointment
29th Jun 20227:00 amRNSQ1 FY23 Trading Update
21st Jun 20227:00 amRNSAnnual Financial Report and Notice of AGM
16th Jun 20229:55 amRNSHolding(s) in Company
9th Jun 20221:17 pmRNSHolding(s) in Company
9th Jun 202212:16 pmRNSDirector/PDMR grant of options
8th Jun 20227:00 amRNSDirector/PDMR Notice
31st May 20227:01 amRNSFY22 Preliminary Results
31st May 20227:00 amRNSCEO Succession
22nd Apr 20227:00 amRNSCEO Succession Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.